Skip to main
TXG
TXG logo

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 58%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics Inc has demonstrated robust growth metrics, particularly with the significant increase in Chromium reaction volumes, indicating resilience in demand despite ongoing pricing pressures in the pharmaceutical sector. The company's consumables segment is projected to experience substantial growth, with expectations of a 5-19x increase by platform by 2027, highlighting strong revenue potential. Additionally, the integration of their diverse product offerings supports the company's strategic position in the life sciences technology market, aligning with the complexities of biological research and analysis.

Bears say

10x Genomics has experienced a contraction in revenues during 2024, attributed to double-digit pricing pressure and flat to modestly lower volumes, with growth not anticipated to accelerate until 2027. The company reported weaker-than-expected Q4 results, including an earnings per share miss and a full-year revenue outlook that fell below market expectations. Additionally, despite some expansion in company segments since 2021, they have not met the high expectations set by analysts, contributing to a decline of over 90% in the stock price since its peak.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 58% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.